Measuring Tesamorelin: Degradation Chemistry, Impurity Classes and LC-MS Detection Methods

RESEARCH · TESAMORELIN · ANALYTICAL METHODS

Measuring Tesamorelin: Degradation Chemistry, Impurity Classes and LC-MS Detection Methods

PurixLab’s Tesamorelin 5mg is a research vial of a synthetic growth hormone-releasing factor (GRF) analogue. Our earlier articles cover a GHRH analogue research overview and its pharmacokinetics and IGF-1 response, and our guide to reading a peptide COA explains chromatography and mass-spectrometry results in general. This article takes an analytical angle instead: what published work says about how the molecule breaks down, what impurity classes a synthetic preparation can carry, and which methods laboratories use to identify it in biological matrices. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.

A minimal modification with an analytical purpose

Tesamorelin, developed as TH9507, is described as an analogue of human growth hormone-releasing factor, hGRF(1-44)NH2, minimally modified by addition of a trans-3-hexenoyl moiety to Tyr1, and was found to be resistant to dipeptidyl aminopeptidase-IV deactivation; compared with natural hGRF(1-44)NH2, the modification slowed in vitro degradation of the peptide in rat, dog and human plasma [1]. The compound was approved in November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [2]. For an analyst, the N-terminal acyl group is the defining structural feature: it changes both the expected accurate mass and the enzymatic fate of the peptide.

Enzymatic cleavage of the parent sequence

The vulnerability being engineered around is well characterised. In plasma, the primary proteolytic cleavage of growth hormone-releasing hormone occurs at the 2-3 amino acid bond; conversion was blocked by a competitive dipeptidylpeptidase IV inhibitor, and D-amino acid substitution at either position 1 or 2 also prevented hydrolysis. Native GRH additionally showed trypsin-like degradation at the 11-12 position, but degradation in plasma occurred primarily by DPP IV [3]. Kinetic work with purified human placental DPP IV measured proteolysis of hGRF and fragments by HPLC and mapped the S1 selectivity of the enzyme, information intended for the design of resistant analogues [4]. Assays of this kind are also what an analytical laboratory uses to predict which metabolites to look for in a sample.

Chemical degradation routes in solution

Independently of enzymes, the GRF sequence has two labile positions. Degradation products of human GRF in aqueous solution were isolated and characterised: cleavage at Asp3-Ala4 dominates at acidic pH, isomerisation of Asp3 to beta-Asp3 predominates above pH 4, and deamidation of Asn8 to beta-Asp8 and Asp8 in about a 4:1 ratio occurs at pH 5 and above and is general base-catalysed; all degradation products had much lower in vitro potency than the parent peptides, and GRF was reported most stable at pH 4-5 [5]. A parallel study of the analogue [Leu27]hGRF(1-32)NH2 at pH 7.4 identified the deamidation products at Asn8 and reported that replacing Asn8 with Ser extended the half-life in phosphate buffer from 202 h to 1550 h, with the Ser8 analogues retaining full potency after 14 days [6]. Later analogue work set out the same three liabilities explicitly: amino-terminal cleavage, isomerisation at residue 8 and oxidation at Met27 [7]. None of this is unique to tesamorelin, but it tells an analyst which peaks a stability-indicating method should resolve.

Solid-state material and residual moisture

Research vials are supplied as lyophilized solids, and solid-state behaviour is a separate question from solution chemistry. The classical freeze-dried protein work on human growth hormone studied chemical decomposition via methionine oxidation and asparagine deamidation as well as irreversible aggregation as a function of residual moisture and headspace oxygen, and found the effects strongly dependent on the formulation, with a glycine/mannitol system giving optimum stability only at low water content and minimal headspace oxygen [8]. We found no published stability programme for lyophilized tesamorelin research material specifically, so moisture and headspace remain stated variables rather than measured ones for any given vial.

Impurity classes in a synthetic preparation

A structured review of peptide-related impurities lists what solid-phase synthesis leaves behind: deletion and insertion sequences, racemisation from Fmoc-deprotection, side-chain protection adducts, oxidation products, dimeric-to-oligomeric species, and counter-ions such as trifluoroacetate, plus degradation routes including succinimide and pyroglutamate formation [9]. Counter-ions are measurable: comparing ion chromatography, capillary electrophoresis and isotachophoresis for acetate, trifluoroacetate and chloride, ion chromatography gave the best results [10]. Their mass matters, too. In a certified-reference-material study of angiotensin II, the trifluoroacetic acid counter-ion was present at nearly 25% by mass and the assigned purity was 691 mg/g, combining quantitative NMR and amino acid analysis [11]. Chromatographic area percent and peptide content by weight are therefore not the same number.

Detecting the intact analogue in biological matrices

Most published methods for this compound come from sports drug testing, where GHRH analogues are prohibited substances. An immunoaffinity purification approach with nano-UHPLC and high-resolution tandem mass spectrometry detected sermorelin, CJC-1293, CJC-1295 and tesamorelin in plasma with recoveries of 19-37% [12], and an expanded assay covering peptides above 2 kDa reported limits of detection of 5-100 pg in urine and 0.1-2 ng in plasma [13]. Magnetic-bead surface chemistries for immunopurification were compared systematically before Quadrupole-Orbitrap analysis of urine, reaching a limit of detection of 0.2 ng/mL [14]. Immunoaffinity is not obligatory: an antibody-free, ultrafiltration-based method achieved limits of detection between 5 and 25 pg/mL in urine, with enhanced recoveries of 59-115%, and noted that sample handling matters because some of these peptides degrade quickly above 4 °C and below pH 7 [15]. A weak cation-exchange solid-phase extraction method on a triple quadrupole detected these analytes near 0.2 ng/mL [16], and a nano-LC quadrupole/orbitrap method validated for screening and confirmation reported limits of detection of 0.5 ng/mL or below [17]. Generic procedures now co-extract several peptide classes from blood [18] or urine [19] in a single run.

Metabolites as analytical targets

Because urinary concentrations are low, metabolite coverage improves sensitivity. An in vitro metabolism study of four larger GHRH analogues, tesamorelin among them, identified nineteen major metabolites, synthesised and characterised them in house, and used them as reference materials for a detection method generally reaching 1 ng/ml or less [20]. Rodent work found intact substances detectable for at least 4 h, while an expected metabolite was confirmed only in a human plasma sample, underlining species differences in metabolism [12].

What remains open

  • No public stability data for research vials. Degradation chemistry is known for the GRF sequence; published shelf-life studies for lyophilized analogue material are not something we located [5,8].
  • Peptide content versus purity. Counter-ion content can be a large mass fraction, so purity needs to be defined by method [11,10].
  • Metabolite reference materials. Many metabolites were available only after in-house synthesis [20].
  • Matrix stability. Handling temperature and pH influence recovery of these peptides from urine [15].

Tesamorelin 5mg at PurixLab

Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tesamorelin 5mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611 · doi:10.1111/j.1742-7843.2007.00008.x
  2. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(2):95-6. PubMed 21283099 · doi:10.1038/nrd3362
  3. Frohman LA, Downs TR, Heimer EP, et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-40. PubMed 2565342 · PMC303858 · doi:10.1172/JCI114049
  4. Bongers J, Lambros T, Ahmad M, et al. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta. 1992;1122(2):147-53. PubMed 1353684 · doi:10.1016/0167-4838(92)90317-7
  5. Bongers J, Heimer EP, Lambros T, et al. Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor. Int J Pept Protein Res. 1992;39(4):364-74. PubMed 1428526 · doi:10.1111/j.1399-3011.1992.tb01596.x
  6. Friedman AR, Ichhpurani AK, Brown DM, et al. Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes. Int J Pept Protein Res. 1991;37(1):14-20. PubMed 1904406 · doi:10.1111/j.1399-3011.1991.tb00727.x
  7. Campbell RM, Stricker P, Miller R, et al. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides. 1994;15(3):489-95. PubMed 7937325 · doi:10.1016/0196-9781(94)90211-9
  8. Pikal MJ, Dellerman K, Roy ML. Formulation and stability of freeze-dried proteins: effects of moisture and oxygen on the stability of freeze-dried formulations of human growth hormone. Dev Biol Stand. 1992;74:21-37; discussion 37-8. PubMed 1592171
  9. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed 25044089 · doi:10.1016/j.jpba.2014.06.012
  10. Mrozik W, Markowska A, Guzik L, et al. Determination of counter-ions in synthetic peptides by ion chromatography, capillary isotachophoresis and capillary electrophoresis. J Pept Sci. 2012;18(3):192-8. PubMed 22252914 · doi:10.1002/psc.1436
  11. Melanson JE, Thibeault MP, Stocks BB, et al. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410(26):6719-6731. PubMed 30143839 · doi:10.1007/s00216-018-1272-7
  12. Knoop A, Thomas A, Fichant E, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016;408(12):3145-53. PubMed 26879649 · PMC4830873 · doi:10.1007/s00216-016-9377-3
  13. Thomas A, Walpurgis K, Tretzel L, et al. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug Test Anal. 2015;7(11-12):990-8. PubMed 26382721 · doi:10.1002/dta.1868
  14. Pont L, Alechaga É, Terrero A, et al. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. J Chromatogr A. 2020;1631:461548. PubMed 32971474 · doi:10.1016/j.chroma.2020.461548
  15. Coppieters G, Deventer K, Polet M, et al. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. J Pharm Biomed Anal. 2022;214:114726. PubMed 35298973 · doi:10.1016/j.jpba.2022.114726
  16. Cristea CD, Radu M, Toboc A, et al. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Anal Biochem. 2023;682:115336. PubMed 37806509 · doi:10.1016/j.ab.2023.115336
  17. Uçaktürk E, Nemutlu E. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. J Pharm Biomed Anal. 2026;268:117207. PubMed 41138283 · doi:10.1016/j.jpba.2025.117207
  18. Thomas A, Thilmany S, Hofmann A, et al. Probing for peptidic drugs (2-10 kDa) in doping control blood samples. Anal Sci Adv. 2022;3(7-8):235-243. PubMed 38716080 · PMC10989627 · doi:10.1002/ansa.202200027
  19. Thomas A, Walpurgis K, Thevis M. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. J Mass Spectrom. 2024;59(1):e4996. PubMed 38197510 · doi:10.1002/jms.4996
  20. Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. PubMed 34665524 · doi:10.1002/dta.3183

Leave a Comment

Your email address will not be published. Required fields are marked *